Intensity-modulated radiation therapy with the central shielding technique for patients with uterine cervical cancer

• Published in: Journal of radiation research Vol. 64; no. 4; pp. 720 - 727
• Main Authors: Torii, Akira, Tomita, Natsuo, Kuno, Mayu, Nishio, Masahiro, Yamada, Yuki, Takaoka, Taiki, Okazaki, Dai, Niwa, Masanari, Kita, Nozomi, Takano, Seiya, Murao, Takayuki, Ogawa, Yasutaka, Hiwatashi, Akio
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 18.07.2023
• Subjects: Cancer; Cancer patients; Care and treatment; Cervical cancer; Chemotherapy; Metastasis; Methods; Oncology, Experimental; Radioisotope brachytherapy; Regular paper; Japan; helical tomotherapy; adverse effects; intensity-modulated radiotherapy; treatment outcome; uterine cervical cancer
• ISSN: 0449-3060; 1349-9157
• DOI: 10.1093/jrr/rrad039

Abstract We aimed to examine outcomes and toxicities of intensity-modulated radiation therapy (IMRT) with the central shielding (CS) technique for patients with uterine cervical cancer. This retrospective study included 54 patients with International Federation of Gynecology and Obstetrics IB-IVA cancer. Whole pelvic radiotherapy or extended-field radiotherapy were performed at the dose of 50.4 Gy in 28 fractions with helical tomotherapy (HT). Six patients had para-aortic lymph node metastases. The CS technique with HT was utilized after a total dose of 28.8–41.4 Gy to reduce doses to the rectum and bladder. The prescribed dose of intracavitary brachytherapy was mainly 18–24 Gy in three or four fractions at point A. Concurrent chemotherapy was used for 47 patients (87%). Median follow-up time was 56 months. Seventeen patients (31%) developed recurrence. The recurrence of the cervix was observed in two patients (4%). The 5-year rates of the locoregional control, progression-free survival (PFS) and overall survival were 79, 66 and 82%, respectively. Among several factors evaluated, histological type of adenocarcinoma was only a significantly worse prognostic factor for PFS by multivariate analysis (hazard ratio, 4.9 [95% confidence interval, 1.3–18], P = 0.018). Grade 2 or higher late toxicities were observed in nine patients (17%). Two patients (4%) each had grade 3 proctitis and grade 3 ileus, respectively. No grade 4 toxicity or treatment-related death was observed. The results suggest that IMRT with the CS technique allows a high local control without increasing the risk of complications for cervical cancer patients.